The global molecular diagnostics market size was valued at USD 9.2 billion in 2019 and is anticipated to register a CAGR of 9.0% over the forecast period. Advancements in molecular diagnostics have facilitated the detection of numerous diseases and are particularly effective when faced with challenging differential diagnosis. Technological advancements in molecular diagnostics are anticipated to substantially drive market growth as they facilitate cost-effectiveness, accuracy, and portability. The commercialization of MinION, an affordable and portable sequencer by Nanopore Technologies, is suitable for use in small laboratories and point-of-care facilities, which is projected to boost the market for molecular diagnostics.
According to the WHO, the average prevalence rate of hospital-acquired infections in 2019 was 4.5% and 7.1% in the U.S. and Europe, respectively. Molecular diagnostics play an essential role in the testing of infectious diseases as they offer quick and effective results. Thus, the growing prevalence of hospital-acquired infections and infectious diseases are further estimated to drive the demand for molecular diagnostics over the forecast period.
Growing funding by governments and numerous organizations for R&D in molecular diagnostics is anticipated to drive the demand for molecular testing. Funding plays a significant role in the product development process. For instance, Accelerate Diagnostics received USD 19.5 million from various entities, such as Oracle Partners, Oracle Institutional Partners, and the Schuler Family Foundation, to enhance the development and sales of infectious disease in vitro diagnostics tests and tools.
The regulatory framework for approvals has always posed major restrictive factors on pharmaceutical, biotechnology, and medical technology industries. Faulty diagnostic kits could provide inaccurate results. Hence, the possibility of causing harm to the patients has driven the FDA to ensure compliance with premarketing regulations. The regulatory environment is already complicated, and the FDA is becoming increasingly careful owing to the growing dependency on molecular diagnostics for making critical medical decisions.
The U.S. FDA also conducts a post-market investigation of in vitro diagnostic device (IVD) products to ensure parity between performance and claims. For instance, a heavy penalty was imposed on Nichols Institute, a subsidiary of Quest Diagnostics, as its test kits produced results that were inaccurate and unreliable. Hence, the stringency of regulations associated with the approval process for molecular diagnostics is limiting the market growth.
In 2019, reagents dominated the overall market for molecular diagnostics. High usage of reagents in molecular diagnostic testing, increased demand for over-the-counter diagnostic tests, and rise in adoption of these tests in nonmedical facilities such as self-testing at home are some of the key growth drivers for the segment. Furthermore, advantages such as standardized results, improved efficiency, and cost-effectiveness are anticipated to support segment growth.
The key players offering reagents are Roche Diagnostics; Illumina Inc.; and Abbott. Reagents is also projected to be the fastest-growing segment over the forecast period. This can be attributed to the growing demand for advanced cancer diagnostic tests and genetic testing in countries with unmet medical needs, such as South Africa and India.
Central laboratories dominated the market for molecular diagnostics in 2019 due to high procedure volume and significant presence of ancillary support in terms of infrastructure and manpower.
Point-of-Care (PoC) is estimated to be the fastest-growing segment over the forecast period. Rising demand for bedside patient care with the booming home healthcare market and increasing market penetration are among the major factors driving the segment growth. Furthermore, rising adoption of self-testing or OTC products, increased awareness of molecular testing among patients, and development in healthcare infrastructure are projected to drive the growth of the segment.
PCR dominated the overall market for molecular diagnostics in 2019. PCR is the most widely used technology in molecular diagnostics. Increased usage and advancements in PCR techniques, e.g., multiplex PCR, are some of the highest impact rendering drivers of this segment.
Sequencing is projected to witness the highest growth rate over the forecast period. This is attributed to factors such as a possible decrease in cost and rise in the portability of DNA sequencers combined with the development of NGS techniques, providing high throughput analysis and sequencing of genomic data.
Furthermore, in situ hybridization (ISH) is projected to witness a substantial growth rate during the forecast period. Increasing prevalence of cancer and the need for early cancer diagnosis are some of the drivers of this segment.
Infectious disease testing dominated the molecular diagnostics market in 2019, given the relapse of infectious diseases, including new strains of multidrug-resistant TB, H1N1, and HIV. Most molecular diagnostic tests are designed for detecting infectious diseases; however, molecular testing is becoming increasingly popular in other spaces, mainly in oncology.
Oncology is expected to be the fastest-growing segment over the forecast period owing to factors such as the increasing prevalence of cancer and the development of advanced diagnostic tests such as companion diagnostics. Companion diagnostics are based on the concept of personalized medicine and involve the identification of biomarker response in a population of patients with the same type of cancer. Moreover, the introduction of such advanced molecular diagnostic technologies will prove to be cost-effective, subsequently driving the growth of the oncology segment.
North America was the largest revenue-generating region for molecular diagnostics in 2019 and this trend is expected to continue over the forecast period. North America dominated the market owing to the presence of a well-established diagnostic infrastructure, technological advancements, patient awareness, and the presence of advanced products in the field of molecular diagnostics.
Increasing government initiatives in Asia Pacific, particularly in economies such as China and India, to improve healthcare infrastructure are expected to drive the demand for molecular diagnostics in the region. Asia Pacific is projected to witness the fastest growth over the forecast period owing to unaddressed clinical needs and the rising demand for improved diagnostic technologies such as molecular testing.
Key players in the global market include Roche Diagnostics; Abbott; Bio-Rad Laboratories, Inc.; Siemens Healthcare GmbH; Alere, Inc.; Bayer AG; Dako; Hologic, Inc. (Gen probe); Sysmex Corporation; Danaher; Johnson & Johnson; Novartis AG; Qiagen N.V.; Becton, Dickinson and Company; Cepheid; and bioMerieux SA.
Key players are adopting various strategies such as mergers and acquisitions to increase their market share. For instance, Qiagen acquired STAT-Dx, a Spanish firm developing next-generation multiplex diagnostics using a novel system based on real-time PCR and Qiagen chemistries. Players are also focusing on expanding their product portfolio. For instance, in 2019, Roche launched the first IVD ROS1 IHC assay-VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody-for the detection of ROS1 protein in cancers.
Report Attribute |
Details |
Market size value in 2020 |
USD 10.1 billion |
Revenue forecast in 2027 |
USD 18.2 billion |
Growth Rate |
CAGR of 9.0% from 2020 to 2027 |
Base year for estimation |
2019 |
Historical data |
2016 - 2018 |
Forecast period |
2020 - 2027 |
Quantitative units |
Revenue in USD million and CAGR from 2020 to 2027 |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
Segments covered |
Product, test location, technology, application region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; Germany; U.K.; France; Italy; Spain; Belgium; Switzerland; Netherlands; Poland; Austria; Greece; Sweden; Turkey; Finland; China; Japan; India; Sri Lanka; Malaysia; Australia; New Zealand; Thailand; Vietnam; Singapore; Brazil; Mexico; Chile; Peru; Colombia; Argentina; South Africa; Saudi Arabia; Jordan; UAE; Qatar; Nigeria; Egypt |
Key companies profiled |
Roche Diagnostics; Abbott; Bio-Rad Laboratories, Inc.; Siemens Healthcare GmbH; Alere, Inc.; Bayer AG; Dako; Hologic, Inc. (Gen probe); Sysmex Corporation; Danaher; Johnson & Johnson; Novartis AG; Qiagen N.V.; Becton, Dickinson and Company; Cepheid; bioMerieux SA. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global molecular diagnostics market report on the basis of product, test location, technology, application, and region:
Product Outlook (Revenue, USD Million, 2016 - 2027)
Instruments
Reagents
Others
Test Location Outlook (Revenue, USD Million, 2016 - 2027)
Point-of-Care
Self-Test or Over the Counter
Central Laboratories
Technology Outlook (Revenue, USD Million, 2016 - 2027)
Polymerase chain reaction (PCR)
PCR, by Type
Multiplex PCR
Other PCR
PCR, by Product
Instruments
Reagents
Others
In Situ Hybridization
Instruments
Reagents
Others
Isothermal Nucleic Acid Amplification Technology (INAAT)
Instruments
Reagents
Others
Chips and Microarrays
Instruments
Reagents
Others
Mass Spectrometry
Instruments
Reagents
Others
Sequencing
Instruments
Reagents
Others
Transcription Mediated Amplification
Instruments
Reagents
Others
Others
Instruments
Reagents
Others
Application Outlook (Revenue, USD Million, 2016 - 2027)
Oncology
Breast Cancer
Prostate Cancer
Colorectal Cancer
Cervical Cancer
Kidney Cancer
Liver Cancer
Blood Cancer
Lung Cancer
Other Cancer
Pharmacogenomics
Infectious Diseases
Methicillin-resistant Staphylococcus Aureus (MRSA)
Clostridium Difficile
Vancomycin-resistant Enterococci (VRE)
Carbapenem-resistant Bacteria
Flu
Respiratory Syncytial Virus (RSV)
Candida
Tuberculosis and Drug-resistant TBA
Meningitis
Gastrointestinal Panel Testing
Chlamydia
Gonorrhea
HIV
Hepatitis C
Hepatitis B
Other Infectious Disease
Genetic Testing
Newborn Screening
Predictive and Presymptomatic Testing
Other Genetic Testing
Neurological Disease
Cardiovascular Disease
Microbiology
Others
Regional Outlook (Revenue, USD Million, 2016 - 2027)
North America
The U.S.
Canada
Europe
The U.K.
Germany
France
Italy
Spain
Belgium
Switzerland
Netherlands
Poland
Austria
Greece
Sweden
Turkey
Finland
Asia Pacific
Japan
China
India
Sri Lanka
Malaysia
Australia
New Zealand
Thailand
Vietnam
Singapore
Latin America
Brazil
Mexico
Chile
Peru
Colombia
Argentina
Middle East & Africa
South Africa
Saudi Arabia
Jordan
UAE
Qatar
Nigeria
Egypt
b. The global molecular diagnostics market size was estimated at USD 9.2 billion in 2019 and is expected to reach USD 10.01 billion in 2020.
b. The global molecular diagnostics market is expected to witness a compound annual growth rate of 9.0% from 2020 to 2027 to reach USD 18.22 billion by 2027.
b. North America held the largest share of 43.90% in 2019 due to the presence of a well-established diagnostic infrastructure, technological advancements, patient awareness, and the presence of advanced products in the field of molecular diagnostics.
b. Key players in the global molecular diagnostics market include Roche Diagnostics; Abbott; Bio-Rad Laboratories, Inc.; Siemens Healthcare GmbH; Alere, Inc.; Bayer AG; Dako; Hologic, Inc. (Gen probe); Sysmex Corporation; Danaher; Johnson & Johnson; Novartis AG; Qiagen N.V.; Becton, Dickinson and Company; Cepheid; and bioMerieux SA.
b. Key factors that are driving the molecular diagnostics market growth include the introduction of technologically advanced products, increasing demand for point-of-care facilities, increasing external funding for R&D, and the growing prevalence of target diseases.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.